<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01502761</url>
  </required_header>
  <id_info>
    <org_study_id>HS-11-00339</org_study_id>
    <nct_id>NCT01502761</nct_id>
  </id_info>
  <brief_title>Intra-arterial Magnesium Administration for Acute Stroke</brief_title>
  <official_title>Intra-arterial Magnesium Therapy: A Novel Platorm for Neuroprotectant Delivery in Acute Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is the second leading cause of death and the leading cause of adult disability
      worldwide. This investigation will address the safety and feasibility of directed,
      intra-arterial Magnesium measurement and therapy, through endovascular access, in acute
      stroke patients. The proposal represents the first study to directly quantify levels of a
      systemically administered neuroprotectant in the region of cerebral ischemia. It also
      establishes a novel endovascular platform for direct delivery of neuroprotective agents to
      ischemic cerebral tissue distal to an occlusive thrombus. This research seeks to improve
      patient care by establishing a novel delivery mechanism for the rescue of threatened brain
      parenchyma that can be administered rapidly following acute stroke. If successful, this
      selective distribution will allow delivery to &quot;at risk&quot; tissue in a rapid manner. Salvage of
      viable, but threatened, penumbral tissue could afford stroke patients an increased
      probability of favorable long term outcome. The investigators hypothesize that endovascular,
      intra-arterial, Magnesium administration will deliver high concentration of this
      neuroprotective agent to otherwise inaccessible cerebral territories, while limiting systemic
      concentrations. The proposed investigation will evaluate the safety and feasibility of this
      novel treatment technique
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No safety issues. Low enrollment secondary to negative stroke studies 2013
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnesium Concentration in Region of Cerebral Ischemia</measure>
    <time_frame>Mg level: 1) Peripheral: Baseline and post-treatment (averaged); 2) Distal: after first pass of the clot retriever</time_frame>
    <description>Peripheral Magnesium Levels, meq/L will be obtained through the femoral sheath at the beginning (baseline) and end (post-treatment) of each case. These will be averaged to obtain a femoral Magnesium level. Magnesium levels distal to the occlusion will be measured at the first pass of the clot retrieving device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Procedure Related Serious Adverse Event</measure>
    <time_frame>intraprocedure, postoperative day 1, 1 month, 3 month</time_frame>
    <description>Periprocedural clinical, radiographic and laboratory data will be collected and analyzed to detect Mg related adverse events. Outcome will be assessed perioperatively and at 24 hours, 30 days (+/- 10 days) and 90 days (+/- 15 days)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Acute Stroke</condition>
  <arm_group>
    <arm_group_label>Regional Intra-arterial Magnesium 0.75g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regional Intra-arterial magnesium only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regional Intra-arterial magnesium 1.5g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regional/ Distal (75/25%) Magnesium 1.5g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regional/ Distal intra-arterial magnesium (75% TD regional- 1.125g / 25% distal-0.375g): 5 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regional/ Distal (50/50%) Magnesium 1.5g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regional/ Distal intra-arterial magnesium (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate</intervention_name>
    <description>Intra-arterial</description>
    <arm_group_label>Regional Intra-arterial Magnesium 0.75g</arm_group_label>
    <arm_group_label>Regional Intra-arterial magnesium 1.5g</arm_group_label>
    <arm_group_label>Regional/ Distal (75/25%) Magnesium 1.5g</arm_group_label>
    <arm_group_label>Regional/ Distal (50/50%) Magnesium 1.5g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with acute cerebral ischemia due to ICA or MCA occlusion,

          2. Patient's clinical attending physician plans mechanical embolectomy procedure as part
             of routine clinical care.

          3. Age 21-95.

        Exclusion Criteria:

          1. Severe renal impairment with creatinine 3.0 or higher,

          2. Myasthenia gravis,

          3. Second or third degree heart block without a pacemaker in place,

          4. Technical inability to navigate microcatheter to target clot,

          5. Patient already enrolled in another experimental treatment trial. Exclusion criteria
             1-3 are all contraindications to magnesium therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William J Mack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Saver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University California Los Angeles: Ronald Reagan and Santa Monica Hospitals</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California University and LA County Hospitals</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2012</study_first_posted>
  <results_first_submitted>June 30, 2017</results_first_submitted>
  <results_first_submitted_qc>July 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2017</results_first_posted>
  <last_update_submitted>July 26, 2017</last_update_submitted>
  <last_update_submitted_qc>July 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>William Mack</investigator_full_name>
    <investigator_title>Assistant Professor of Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>Magnesium</keyword>
  <keyword>endovascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Regional Intra-arterial Magnesium 0.75g</title>
          <description>Regional only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
Magnesium Sulfate: Intra-arterial</description>
        </group>
        <group group_id="P2">
          <title>Regional Intra-arterial Magnesium 1.5g</title>
          <description>Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
Magnesium Sulfate: Intra-arterial</description>
        </group>
        <group group_id="P3">
          <title>Regional/ Distal (75/25%) Magnesium 1.5g</title>
          <description>Regional/ Distal(75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
Magnesium Sulfate: Intra-arterial</description>
        </group>
        <group group_id="P4">
          <title>Regional/ Distal (50/50%) Magnesium 1.5g</title>
          <description>Regional/ Distal (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients
Magnesium Sulfate: Intra-arterial</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>4 patients were enrolled (regional intra-arterial Magnesium 0.75g) before the study was stopped (not due to safety concerns). They were all enrolled in the first group</population>
      <group_list>
        <group group_id="B1">
          <title>Regional Intra-arterial Magnesium 0.75g</title>
          <description>Regional only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
Magnesium Sulfate: Intra-arterial</description>
        </group>
        <group group_id="B2">
          <title>Regional Intra-arterial Magnesium 1.5g</title>
          <description>Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
Magnesium Sulfate: Intra-arterial</description>
        </group>
        <group group_id="B3">
          <title>Regional/ Distal (75/25%) Magnesium 1.5g</title>
          <description>Regional/ Distal(75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
Magnesium Sulfate: Intra-arterial</description>
        </group>
        <group group_id="B4">
          <title>Regional/ Distal (50/50%) Magnesium 1.5g</title>
          <description>Regional/ Distal (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients
Magnesium Sulfate: Intra-arterial</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.25" spread="13.25"/>
                    <measurement group_id="B5" value="68.25" spread="13.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Magnesium Concentration in Region of Cerebral Ischemia</title>
        <description>Peripheral Magnesium Levels, meq/L will be obtained through the femoral sheath at the beginning (baseline) and end (post-treatment) of each case. These will be averaged to obtain a femoral Magnesium level. Magnesium levels distal to the occlusion will be measured at the first pass of the clot retrieving device.</description>
        <time_frame>Mg level: 1) Peripheral: Baseline and post-treatment (averaged); 2) Distal: after first pass of the clot retriever</time_frame>
        <population>Enrollment only occurred in the first arm (lowest dose) of the study as the arms were planned to enroll sequentially. The study was not stopped due to safety concerns</population>
        <group_list>
          <group group_id="O1">
            <title>Regional Intra-arterial Magnesium 0.75g</title>
            <description>Regional only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
Magnesium Sulfate: Intra-arterial</description>
          </group>
          <group group_id="O2">
            <title>Regional Intra-arterial Magnesium 1.5g</title>
            <description>Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
Magnesium Sulfate: Intra-arterial</description>
          </group>
          <group group_id="O3">
            <title>Regional/ Distal (75/25%) Magnesium 1.5g</title>
            <description>Regional/ Distal(75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
Magnesium Sulfate: Intra-arterial</description>
          </group>
          <group group_id="O4">
            <title>Regional/ Distal (50/50%) Magnesium 1.5g</title>
            <description>Regional/ Distal (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients
Magnesium Sulfate: Intra-arterial</description>
          </group>
        </group_list>
        <measure>
          <title>Magnesium Concentration in Region of Cerebral Ischemia</title>
          <description>Peripheral Magnesium Levels, meq/L will be obtained through the femoral sheath at the beginning (baseline) and end (post-treatment) of each case. These will be averaged to obtain a femoral Magnesium level. Magnesium levels distal to the occlusion will be measured at the first pass of the clot retrieving device.</description>
          <population>Enrollment only occurred in the first arm (lowest dose) of the study as the arms were planned to enroll sequentially. The study was not stopped due to safety concerns</population>
          <units>meq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Distal Mg level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.475" spread=".3403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral Mg level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.513" spread=".2462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Procedure Related Serious Adverse Event</title>
        <description>Periprocedural clinical, radiographic and laboratory data will be collected and analyzed to detect Mg related adverse events. Outcome will be assessed perioperatively and at 24 hours, 30 days (+/- 10 days) and 90 days (+/- 15 days)</description>
        <time_frame>intraprocedure, postoperative day 1, 1 month, 3 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regional Intra-arterial Magnesium 0.75g</title>
            <description>Regional only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
Magnesium Sulfate: Intra-arterial</description>
          </group>
          <group group_id="O2">
            <title>Regional Intra-arterial Magnesium 1.5g</title>
            <description>Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
Magnesium Sulfate: Intra-arterial</description>
          </group>
          <group group_id="O3">
            <title>Regional/ Distal (75/25%) Magnesium 1.5g</title>
            <description>Regional/ Distal(75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
Magnesium Sulfate: Intra-arterial</description>
          </group>
          <group group_id="O4">
            <title>Regional/ Distal (50/50%) Magnesium 1.5g</title>
            <description>Regional/ Distal (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients
Magnesium Sulfate: Intra-arterial</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Procedure Related Serious Adverse Event</title>
          <description>Periprocedural clinical, radiographic and laboratory data will be collected and analyzed to detect Mg related adverse events. Outcome will be assessed perioperatively and at 24 hours, 30 days (+/- 10 days) and 90 days (+/- 15 days)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Regional Intra-arterial Magnesium 0.75g</title>
          <description>Regional only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
Magnesium Sulfate: Intra-arterial</description>
        </group>
        <group group_id="E2">
          <title>Regional Intra-arterial Magnesium 1.5g</title>
          <description>Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
Magnesium Sulfate: Intra-arterial</description>
        </group>
        <group group_id="E3">
          <title>Regional/ Distal (75/25%) Magnesium 1.5g</title>
          <description>Regional/ Distal(75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
Magnesium Sulfate: Intra-arterial</description>
        </group>
        <group group_id="E4">
          <title>Regional/ Distal (50/50%) Magnesium 1.5g</title>
          <description>Regional/ Distal (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients
Magnesium Sulfate: Intra-arterial</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Parotiditis with sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>increased blood glucose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ischemic change on brain imaging</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hemorrhagic Transformation of stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was terminated early (with enrollment only in the first arm) by the investigators due to low enrollment (given results of relevant studies at the time) . There were no safety concerns with the trial or the agent.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. William J Mack</name_or_title>
      <organization>University of Southern California</organization>
      <phone>323 442 7512</phone>
      <email>william.mack@med.usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

